News Releases

News Releases
  Date Title and Summary View
Sep 17, 2002
September 17, 2002; San Carlos, Calif. — ChemoCentryx, Inc. today announced the initiation of a Phase I clinical trial in the United Kingdom by its partner, Tularik Inc., (Nasdaq: TLRK), for T487, an oral anti-inflammatory drug candidate. T487 is the most advanced clinical candidate in ChemoCentryx's broad pipeline ...
Page: FirstPrevious ...
= add release to Briefcase